Creative Planning Acquires 23,768 Shares of Koninklijke Philips (NYSE:PHG)

Creative Planning increased its position in Koninklijke Philips (NYSE:PHG) by 39.3% during the third quarter, Holdings Channel.com reports. The firm owned 84,263 shares of the technology company’s stock after buying an additional 23,768 shares during the quarter. Creative Planning’s holdings in Koninklijke Philips were worth $2,757,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mondrian Investment Partners LTD raised its position in Koninklijke Philips by 45.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 9,553,058 shares of the technology company’s stock valued at $191,061,000 after buying an additional 2,971,008 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Koninklijke Philips by 27.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,036,336 shares of the technology company’s stock worth $101,718,000 after purchasing an additional 864,951 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Koninklijke Philips by 36.4% during the 1st quarter. Russell Investments Group Ltd. now owns 1,410,067 shares of the technology company’s stock valued at $28,201,000 after acquiring an additional 376,244 shares during the last quarter. Millennium Management LLC boosted its position in shares of Koninklijke Philips by 822.0% during the 2nd quarter. Millennium Management LLC now owns 1,120,521 shares of the technology company’s stock valued at $28,237,000 after acquiring an additional 998,995 shares during the last quarter. Finally, Natixis Advisors LLC boosted its position in shares of Koninklijke Philips by 5.2% during the 2nd quarter. Natixis Advisors LLC now owns 930,085 shares of the technology company’s stock valued at $23,438,000 after acquiring an additional 46,268 shares during the last quarter. 13.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Monday, July 15th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Koninklijke Philips Price Performance

Shares of Koninklijke Philips stock opened at $31.67 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The company has a market cap of $29.77 billion, a PE ratio of -59.75, a P/E/G ratio of 1.05 and a beta of 0.74. The business has a 50 day moving average of $31.10 and a 200 day moving average of $27.69. Koninklijke Philips has a 52 week low of $18.06 and a 52 week high of $32.91.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings results on Monday, July 29th. The technology company reported $0.32 earnings per share for the quarter. The company had revenue of $4.80 billion for the quarter. Koninklijke Philips had a positive return on equity of 10.15% and a negative net margin of 2.35%. As a group, equities research analysts forecast that Koninklijke Philips will post 1.59 earnings per share for the current year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.